• breast cancer - HR positive
• es-BC - HR positive - (neo)adjuvant (NA) 2
• es-BC - HR-positive - 1st line (L1) 1
• la/mBC - HR positive 2
• la/mBC - HR positive - (neo)adjuvant (NA) 3
• la/mBC - HR positive - NA - PIK3CA mutant
• la/mBC - HR-positive - 1st line (L1) 13
• la/mBC - HR positive - L1 - PIK3CA mutant 1
• la/mBC - HR-positive - 2nd line (L2) 20
• la/mBC - HR positive - L2 - all population 1
• la/mBC - HR positive - L2 - PIK3CA mutant 1

 

• phosphoinositide 3-kinase (PI3K) inhibitor
• taselisib based treatment
• taselisib plus letrozole

• versus all
• vs endocrine therapy
• vs letrozole

  All patients HER2 negative Postmenopausal status

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

es-BC - HR-positive - 1st line (L1), phosphoinositide 3-kinase (PI3K) inhibitor vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;